...
首页> 外文期刊>Cell death & disease. >ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts
【24h】

ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts

机译:ARHI(DIRAS3)介导的自噬相关细胞死亡增强了卵巢癌细胞系和异种移植物中对顺铂的化学敏感性

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Autophagy can sustain or kill tumor cells depending upon the context. The mechanism of autophagy-associated cell death has not been well elucidated and autophagy has enhanced or inhibited sensitivity of cancer cells to cytotoxic chemotherapy in different models. ARHI ( DIRAS3 ), an imprinted tumor suppressor gene, is downregulated in 60% of ovarian cancers. In cell culture, re-expression of ARHI induces autophagy and ovarian cancer cell death within 72?h. In xenografts, re-expression of ARHI arrests cell growth and induces autophagy, but does not kill engrafted cancer cells. When ARHI levels are reduced after 6 weeks, dormancy is broken and xenografts grow promptly. In this study, ARHI-induced ovarian cancer cell death in culture has been found to depend upon autophagy and has been linked to G1 cell-cycle arrest, enhanced reactive oxygen species (ROS) activity, RIP1/RIP3 activation and necrosis. Re-expression of ARHI enhanced the cytotoxic effect of cisplatin in cell culture, increasing caspase-3 activation and PARP cleavage by inhibiting ERK and HER2 activity and downregulating XIAP and Bcl-2. In xenografts, treatment with cisplatin significantly slowed the outgrowth of dormant autophagic cells after reduction of ARHI, but the addition of chloroquine did not further inhibit xenograft outgrowth. Taken together, we have found that autophagy-associated cancer cell death and autophagy-enhanced sensitivity to cisplatin depend upon different mechanisms and that dormant, autophagic cancer cells are still vulnerable to cisplatin-based chemotherapy.
机译:自噬可以根据情况维持或杀死肿瘤细胞。自噬相关的细胞死亡的机制尚未得到很好的阐明,并且自噬在不同模型中增强或抑制了癌细胞对细胞毒性化学疗法的敏感性。 ARHI(DIRAS3)是一种印迹的抑癌基因,在60%的卵巢癌中被下调。在细胞培养中,ARHI的重新表达可在72小时内诱导自噬和卵巢癌细胞死亡。在异种移植物中,ARHI的重新表达会阻止细胞生长并诱导自噬,但不会杀死移植的癌细胞。当6周后ARHI水平降低时,休眠被打破,异种移植迅速生长。在这项研究中,发现ARHI诱导的卵巢癌细胞在培养中的死亡取决于自噬,并且与G1细胞周期停滞,活性氧(ROS)活性增强,RIP1 / RIP3活化和坏死有关。通过抑制ERK和HER2活性并下调XIAP和Bcl-2,ARHI的重新表达增强了顺铂在细胞培养中的细胞毒性作用,增加了caspase-3激活和PARP裂解。在异种移植物中,用顺铂处理可显着减慢ARHI降低后休眠的自噬细胞的生长,但添加氯喹并不能进一步抑制异种移植的生长。两者合计,我们发现自噬相关的癌细胞死亡和对顺铂的自噬增强敏感性取决于不同的机制,并且休眠的自噬癌细胞仍然易受基于顺铂的化疗的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号